13F reference period
Q2 2026
Security Snapshot
Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE) Institutional Ownership
CUSIP: 578784100
13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026
Institutions Reporting
160
Shares (Excl. Options)
58.53M
Full value: 58,534,404 · shares · 30 Jun 2026Price
$29.84
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.001 par value per share
- Symbol
- MAZE on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 58,534,404
- Total 13F value
- $1,745,780,907
- Portfolio coverage rank
- 0%
- Share change
- +6,239,143
- Value change
- +$185,206,340
- Number of holders
- 160
- Shares outstanding
- 55,150,259
- SEC-reported price per share
- $27.18
- Insider filing price
- $27.18
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- MAZE - Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 578784100.
- 160 institutions reported positions in Q2 2026.
- 9 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 164 to 160 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$1.54B
Full value: $1,543,189,088 · USD · 31 Mar 2026.$1.75B
Full value: $1,745,780,907 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 160 institutions filings for Q2 2026.
Security key
578784100
13F reference period
Q2 2026
13F holders
160
13D/G owners
9
CIK / CUSIP context first
Open Q2 2026 holders
MAZE full holder history
Maze Therapeutics, Inc. SEC filings
Maze Therapeutics, Inc. company facts
Maze Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 578784100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
9
Security
MAZE
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 9.3% | -33% | $179,808,372 | -$64,304,000 | 4,473,958 | -26% | Third Rock Ventures IV, L.P. | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 9% | +16% | $174,515,671 | +$39,762,017 | 4,342,266 | +30% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| ARCH Venture Fund X, L.P. | 9.4% | $36,215,266 | 4,120,053 | ARCH Venture Fund X, L.P. | 31 Mar 2025 | |||
| Deep Track Capital, LP | 9% | +30% | $59,431,096 | +$13,927,661 | 3,948,910 | +31% | Deep Track Capital, LP | 30 Jun 2025 |
| BlackRock, Inc. | 5.4% | $88,865,731 | 2,978,114 | BlackRock, Inc. | 30 Jun 2026 | |||
| JANUS HENDERSON GROUP PLC | 5.8% | -21% | $78,390,380 | -$9,531,082 | 2,858,876 | -11% | JANUS HENDERSON GROUP PLC | 31 Mar 2026 |
| Matrix Capital Management Company, LP | 3.5% | -37% | $42,880,026 | -$21,586,725 | 1,653,684 | -33% | Matrix Capital Management Company, LP | 30 Sep 2025 |
| GV 2019, L.P. | 2.9% | -52% | $57,528,994 | -$42,419,680 | 1,388,583 | -42% | Alphabet Holdings LLC | 31 Dec 2025 |
| Foresite Capital Fund IV, L.P. | 1.4% | -70% | $15,790,022 | -$47,922,789 | 608,948 | -75% | James Tananbaum | 30 Sep 2025 |
As of 30 Jun 2026,
160
institutional investors reported holding
shares of
Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE).
This represents
106%
of the company’s total
outstanding shares.
58.53M
Full value: 58,534,404 · shares · 30 Jun 202655.15M
Full value: 55,150,259 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
87%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 9.1% | 5,032,915 | +10% | 3.3% | $150,182,184 |
| TRV GP IV, LLC | 8.1% | 4,473,958 | 0% | 53% | $133,502,907 |
| ARCH Venture Management, LLC | 7.5% | 4,120,053 | 0% | 11% | $122,983,582 |
| Deep Track Capital, LP | 6.8% | 3,732,569 | +7.3% | 1.6% | $111,379,859 |
| BlackRock, Inc. | 6.4% | 3,502,841 | +36% | 0% | $104,524,775 |
| Jupiter Topco LLC | 6.2% | 3,408,045 | 0% | 0.04% | $101,764,224 |
| T. Rowe Price Investment Management, Inc. | 4.7% | 2,603,682 | 0.05% | $77,694,000 | |
| Logos Global Management LP | 3.5% | 1,935,000 | +57% | 2.5% | $57,740,400 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.2% | 1,778,222 | +24% | 0% | $53,062,144 |
| a16z Capital Management, L.L.C. | 3.1% | 1,702,225 | 0% | 0.36% | $50,794,394 |
| Venrock Adviser, LLC | 2.9% | 1,602,034 | 0% | 1.4% | $47,804,695 |
| Alphabet Inc. | 2.5% | 1,388,583 | 0% | 0.04% | $41,435,317 |
| BRAIDWELL LP | 2.1% | 1,140,040 | 1.3% | $34,018,794 | |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 2% | 1,107,814 | +197% | 0.19% | $33,057,170 |
| FMR LLC | 1.9% | 1,056,959 | +22% | 0% | $31,539,649 |
| General Catalyst Group Management, LLC | 1.9% | 1,035,910 | 0% | 16% | $30,911,554 |
| STATE STREET CORP | 1.8% | 997,533 | +57% | 0% | $29,766,385 |
| JPMORGAN CHASE & CO | 1.7% | 964,011 | +1549% | 0% | $27,995,382 |
| Driehaus Capital Management LLC | 1.7% | 954,886 | +50% | 0.17% | $28,493,798 |
| TRV GP V, LLC | 1.7% | 950,800 | 0% | 5.7% | $28,371,872 |
| MARSHALL WACE, LLP | 1.7% | 914,572 | +194% | 0.02% | $27,290,827 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.6% | 858,054 | +43% | 0% | $25,608,436 |
| CITADEL ADVISORS LLC | 1.5% | 852,676 | +9.9% | 0.01% | $25,443,852 |
| Casdin Capital, LLC | 1.5% | 843,857 | +11% | 1.3% | $25,180,693 |
| ArrowMark Colorado Holdings LLC | 1.4% | 767,383 | 0% | 0.95% | $22,898,709 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
7
Headline period
Q2 2026
Rows shown
1-7 of 7
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 133,791 | $3,634,243 | +$2,438,750 | $27.18 | 15 |
| 2026 Q2 | 58,534,404 | $1,745,780,907 | +$185,206,340 | $29.84 | 160 |
| 2026 Q1 | 51,677,471 | $1,543,189,088 | +$68,960,987 | $29.85 | 164 |
| 2025 Q4 | 48,370,369 | $2,003,833,642 | +$199,439,391 | $41.43 | 144 |
| 2025 Q3 | 42,970,633 | $1,114,223,528 | +$108,250,260 | $25.93 | 93 |
| 2025 Q2 | 38,836,437 | $476,719,891 | -$14,337,293 | $12.27 | 74 |
| 2025 Q1 | 40,038,674 | $441,393,439 | +$441,263,796 | $11.01 | 68 |